News on research and diagnostics for metabolic disorders and metabolic diseases.
While results are preliminary, the test could potentially be used in lieu of a liver biopsy.
The collaboration aims at automating the processing of up to 96 liquid biopsy samples at one time using Enable Bio's (ADAP) technology for immunoassays.
The test uses machine learning algorithms to assess predictive biomarkers and electronic health record information to identify progressive kidney disease.
The company's cofounders will pay $500,000 each to settle allegations by the US Department of Justice that they submitted false claims to Medicare.
Decreased sales in the firm's centralized and point-of-care business and diabetes care business were partially offset by strong growth in the molecular diagnostics business.
